Example: Heart Attack

Search clinical trials for: Ferric Compounds

Total 31 results

NCT04510870

Not yet recruiting

Iron Deficiency as an Ignored Cause of Infertility

Conditions: Iron Deficiency; Infertility
NCT02628860

Completed

Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy

Conditions: Pancreatic Cancer; Anemia
NCT04083755

Recruiting

Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With LEAD (IRONPAD)

Conditions: Anemia; Peripheral Arterial Occlusive Disease
NCT03707249

Completed

Iron Status and Cardiopulmonary Physiology

Conditions: Iron-deficiency; Ventricular Function; Pulmonary Vascular Resistance Abnormality; Altitude Hypoxia
NCT00994318

Completed

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions: Iron Deficiency Anaemia; Chronic Kidney Disease
NCT00982007

Completed

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Conditions: Iron Deficiency Anemia
NCT04046263

Recruiting

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Conditions: Peritoneal Dialysis Complication; Hyperphosphatemia; Hypoalbuminemia
NCT03010072

Completed

The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum

Conditions: Endstage Renal Disease
NCT00882414

Terminated

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

Conditions: Thrombocytosis; Iron-Deficiency Anemia
NCT01069692

Completed

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

Conditions: Hyperphosphatemia; Chronic Kidney Disease
NCT00750295

Completed

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

Conditions: Chronic Kidney Disease
NCT03074591

Recruiting

Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction

Conditions: Iron-deficiency; Heart Failure
NCT04626414

Recruiting

Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

Conditions: Anemia, Iron Deficiency
NCT04625530

Recruiting

Perioperative Management in Gynaecological Carcinoma Surgery

Conditions: Gynaecological Carcinoma
NCT02399449

Completed

IV Iron Safety: Evaluation of Iron Species in Healthy Subjects

Conditions: Anemia
NCT00223977

Completed

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

Conditions: Iron Deficiency Anemia
NCT00223938

Unknown status

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Conditions: Anemia
NCT00704483

Completed

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

Conditions: Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
NCT01213680

Completed

Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease

Conditions: Inflammatory Bowel Disease
NCT01503736

Completed

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease

Conditions: Hyperphosphatemia; End Stage Renal Disease; ESRD
NCT01975272

Unknown status

The Use of Iron Therapy for Patients With Anemia After Surgery

Conditions: Postoperative Anaemia
NCT02680756

Completed

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

Conditions: Anemia, Iron-Deficiency; Inflammatory Bowel Disease; Crohn's Disease
NCT01213992

Completed

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD

Conditions: Non-dialysis Dependent Chronic Kidney Disease
NCT01213979

Completed

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Conditions: Non-hematological Malignancies
NCT03610230

Recruiting

Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients

Conditions: Iron Deficiency Anemia Treatment